Bariatric Surgery Reduces Lifetime Cardiovascular Risk More Than GLP-1 Agonists

Obesity remains a primary driver of atherosclerotic cardiovascular disease, necessitating aggressive intervention to manage metabolic and inflammatory pathways [1]. While lifestyle modifications often yield modest results, metabolic and bariatric surgery has historically served as the benchmark for sustained weight loss, with long-term data demonstrating a reduction in all-cause mortality (adjusted hazard ratio 0.71, 95% confidence interval 0.54 to 0.92) compared to usual care [2, 3]. The clinical landscape has shifted with the emergence of glucagon-like peptide-1 receptor agonists, which offer potent pharmacological alternatives for weight management and the reduction of major adverse cardiovascular events (a composite clinical endpoint typically including myocardial infarction, stroke, and cardiovascular death) [4, 5]. Current guidelines emphasize early risk factor modification to prevent these events, yet the comparative durability of surgical versus pharmacological strategies remains a point of clinical debate [6]. Recent meta-analyses of observational data suggest that bariatric surgery is associated with a 35% lower risk of major adverse cardiovascular events (hazard ratio 0.65, 95% confidence interval 0.51 to 0.83) when compared directly to glucagon-like peptide-1 receptor agonist therapy [7]. A new study now provides a direct comparison of these two modalities, focusing on their respective impacts on projected cardiovascular risk over a patient's lifetime.